Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

(Reuters) -Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico in 2025, Chief Financial Officer Lucas Montarce said on Monday at the ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive — and covered an exclusive trip for leaders to attend last summer’s ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...

Discouraging news from a rival dampened sentiment on the pharmaceutical giant's shares. This concerned a next-generation weight loss drug. That negative investor reaction was directed at companies ...

All right. So, I think we should get started here. For those of you who don't know me, my name is Dave Risinger. I'm responsible for diversified biopharma research at Leerink Partners. It's very ...

Presiding over the upward trajectory of Eli Lilly over the last eight years has been paying off nicely for CEO David Ricks. In 2024, his compensation package grew to $29.2 million, according to ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” fourth quarter 2024 investor letter. A copy of ...